Latest news

{{'Mon, 20 Oct 2025 07:00:00 -0400' | dateFormatUsFilter}}

Novo Nordisk to present new data in oral semaglutide 25 mg (Wegovy® in a pill*) and obesity pipeline at ObesityWeek® 2025

Read more

{{'Fri, 17 Oct 2025 17:15:00 -0400' | dateFormatUsFilter}}

FDA approves Novo Nordisk's oral semaglutide for cardiovascular (CV) risk reduction in adults with type 2 diabetes who are at high risk, including those who have not had a prior CV event

Read more

{{'Mon, 29 Sep 2025 08:05:00 -0400' | dateFormatUsFilter}}

Novo Nordisk resubmits Awiqli® to the FDA with potential to be the first once-weekly basal insulin treatment for adults with type 2 diabetes

Read more

News archive

Latest on compounded and counterfeit products and other important information about semaglutide.

Visit semaglutide.com

Career opportunities

Here are our current job openings. If we don’t currently have an opening in your area of interest, we encourage you to create a job agent and candidate profile.